Walleye Capital
OVID icon

Walleye Capital’s Ovid Therapeutics OVID Stock Holding History

Walleye Capital’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-443,362
Closed -$984K – 5068
2026
Q1 		$984K Sell
443,362
-86,658
-16% -$155K ﹤0.01% 2088
2025
Q4 		$864K Sell
530,020
-66,697
-11% -$103K ﹤0.01% 2560
2025
Q3 		$776K Buy
+596,717
New +$517K ﹤0.01% 2290

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Walleye Capital's OVID Position: Q2 2026 in Review

Walleye Capital sold out of Ovid Therapeutics (OVID) in Q2 2026, closing a stake of 443,362 shares — an estimated $984K sold.

Walleye Capital first reported a position in OVID in Q3 2025 and held it in 3 quarters. The position peaked at $984K in Q1 2026. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Walleye Capital reported no remaining Ovid Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 443,362 Ovid Therapeutics shares in Q2 2026, an estimated $984K.
  • Walleye Capital first reported a position in Ovid Therapeutics in Q3 2025 and held it in 3 quarters.
  • Walleye Capital's Ovid Therapeutics position peaked at $984K in Q1 2026.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.